CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Bougival, France

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • Featured

    A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

    * Phase 1 dose escalation of MRTX849 to determine maximum tolerated dose. * Phase 1b expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 to recommend Phase 2 regimens. * Separate Phase 2 cohorts of patients stratified by histological diagnosis for evaluation of clinical activity of MRTX849. * MRTX849 will be administered orally in a continuous regimen. The **Pilot Phase 1b Combination with Pembrolizumab** arm of the study will evaluate the safety, tolerability, PK, and clinical activity of the investigational study agent, MRTX849, in combination with pembrolizumab in patients with NSCLC. The **Pilot Phase 1b Combination with Cetuximab** arm of the study will evaluate the safety, tolerability, PK, and clinical activity of MRTX849 in combination with cetuximab in patients with CRC. Lastly, the **Pilot Phase 1b Combination with Afatinib** arm of the study will evaluate the safety, tolerability, PK and clinical activity of MRTX849 in combination with afatinib in patients with NSCLC.

    Phase

    1/2

    Span

    Sponsor

    Orange, California

    Recruiting

  • Featured

    A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

    For more information, please contact Incyte Corporation at 1.855.463.3463 or visit **[www.incyteclinicaltrials.com](https://www.incyteclinicaltrials.com/)**

    Phase

    3

    Span

    Sponsor

    Orange, California

    Recruiting

  • Featured

    A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

    * Interventional Study * Estimated Enrollment:170 participants * Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations. * This study consists of 3 cohorts that will have study drug administered in parallel, Cohort A, Cohort B, and Cohort C. * There is no difference in the treatment regimen between the cohorts.

    Phase

    2

    Span

    Sponsor

    Orange, California

    Recruiting

  • Featured

    Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy

    Phase

    3

    Span

    Sponsor

    Flamel Ireland Limited

    Orange, California

    Recruiting

  • Featured

    A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

    * Phase 1/1b to establish the maximum tolerated dose of the combination of study drugs in patients with advanced solid tumor malignancies with a KRAS G12C mutation. * Phase 2 to evaluate clinical activity of the combination of study drugs in selected solid tumor malignancies with KRAS G12C mutation.

    Phase

    1/2

    Span

    Sponsor

    Orange, California

    Recruiting

  • Featured

    A Phase 1b, Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With REGN2810 (Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

    Phase

    1/2

    Span

    Sponsor

    Orange, California

    Recruiting

  • Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder

    Phase

    2

    Span

    140 weeks

    Sponsor

    Otsuka Pharmaceutical Development & Commercialization, Inc.

    Orange, California

    Recruiting

  • ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

    Phase

    N/A

    Span

    183 weeks

    Sponsor

    Persephone Biosciences

    Orange, California

    Recruiting

    Healthy Volunteers

  • VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants with Early Alzheimer's Disease

    Phase

    1/2

    Span

    117 weeks

    Sponsor

    Voyager Therapeutics

    Orange, California

    Recruiting

  • Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    Phase

    3

    Span

    132 weeks

    Sponsor

    Neurocrine Biosciences

    Orange, California

    Recruiting

1-10 of 557
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 703.538.7600
Toll Free: 888.838.5578

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information